Chronic pain is maintained in part by central sensitization, a phenomenon of synaptic
plasticity, and increased neuronal responsiveness in central pain pathways after painful …

Background Acute pain is a warning mechanism that exists to prevent tissue damage,
however pain can outlast its protective purpose and persist beyond injury, becoming …

Purpose Over half of all cancer patients receiving taxane-, platinum-, or vinca alkaloid-based
chemotherapy experience chemotherapy-induced peripheral neuropathy (CIPN), which …

Chemotherapy‐induced peripheral neuropathy (CIPN) has a high prevalence but is poorly
managed for cancer patients due to the lack of reliable and sensitive diagnostic techniques …

When peripheral neuropathy occurs due to chemotherapy treatment, it is referred to as
chemotherapy-induced peripheral neuropathy (CIPN). Typically, symptoms are sensory …

Paclitaxel-induced peripheral neuropathy is a common adverse effect during paclitaxel
treatment resulting in sensory abnormalities and neuropathic pain during chemotherapy and …

The proinflammatory cytokine interleukin-17 (IL-17) is implicated in pain regulation.
However, the synaptic mechanisms by which IL-17 regulates pain transmission are …

Bortezomib, a first-generation proteasome inhibitor widely used in chemotherapy for
hematologic malignancy, has effective anti-cancer activity but often causes severe …

Neuropathic cancer pain (NCP) is caused by nerve damage attributable to the cancer per
se, and/or treatments including chemotherapy, radiotherapy, and surgery; the prevalence is …

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a progressive,
enduring, and often irreversible adverse effect of many antineoplastic agents, among which …